COMMUNIQUÉS West-GlobeNewswire

IO Biotech Provides Corporate Update
30/01/2026
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune- [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
30/01/2026
Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top- [...]
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
30/01/2026
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the parent company of Alps Life Sciences Inc. (“ Alps Holdco ”), a fully integrated biotechnology research [...]
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
30/01/2026
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy [...]
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
30/01/2026
Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of Pain [...]
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
30/01/2026
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international [...]
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations
30/01/2026
AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new standard of [...]
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
30/01/2026
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing [...]
Immunocore announces R&D leadership evolution
30/01/2026
Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles [...]
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
30/01/2026
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidence If approved [...]
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
30/01/2026
PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
30/01/2026
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024 Fourth quarter 2025 Dupixent ® global net sales (recorded by Sanofi [...]
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
30/01/2026
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population The company is finalizing the [...]
PhenQ 2026: OTC appetite suppressant search analysis for phentermine alternatives
30/01/2026
New YORK City, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Visit PhenQ Official Website Here TL;DR Summary: Most people are reluctant to discuss weight reduction because it is such a delicate subject. The majority of people [...]
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
30/01/2026
THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 [...]
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
30/01/2026
ORION CORPORATION PRESS RELEASE 30 JANUARY 2026 at 9.30 EET Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026 Orion will publish Financial Statement Release for 2025 on [...]
Vaxcyte Announces Pricing of $550 Million Public Offering
30/01/2026
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is [...]
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]

Pages